QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-10-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023
|
| _version_ | 1797916138497114112 |
|---|---|
| author | Hiromi Okuyama Seigo Nakamura Sadako Akashi-Tanaka Terumasa Sawada Takashi Kuwayama Satoko Handa Yasuhisa Kato |
| author_facet | Hiromi Okuyama Seigo Nakamura Sadako Akashi-Tanaka Terumasa Sawada Takashi Kuwayama Satoko Handa Yasuhisa Kato |
| author_sort | Hiromi Okuyama |
| collection | DOAJ |
| description | Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of Cancer Therapy-Breast (FACT-B), as a measure of health-related quality of life (HRQoL).Materials and Methods: Stage I–III HER2-negative breast cancer patients from the previous study were included. They received either four cycles of nab-PTX (100 mg/m2 days 1/8/15) every 4 weeks, or DTX (75 mg/m2 day 1) every 3 weeks, both followed by four cycles of 5-fluorouracil/ epirubicin/cyclophosphamide (FEC). Patients completed a health-related quality-of-life questionnaire at baseline, after one and four cycles of taxanes, before administration of FEC, and after administration of one and four cycles of FEC.Results: Thirty-six eligible patients were enrolled. The baseline characteristics of the two groups were well balanced. FACT-B scores at baseline and after four cycles of taxanes were 115/108 (DTX/nab-PTX) and 99/92, respectively. There were no significant differences between DTX and nab-PTX for FACT-B, FACT-B-Trial Outcome Index (FACT-B-TOI) and FACT-General. FACT-B and FACT-B TOI scores tended to decrease after one cycle and after four cycles of chemotherapy which did not recover to the baseline scores through the end of chemotherapy in each group.Conclusion: There were no significant safety differences between nab-PTX and DTX. HRQoL tended to decrease during taxane-based anticancer treatment, with no significant differences between the treatments. We suggest that the HRQoL questionnaire has limited ability to evaluate different chemotherapy schedules. Trial registration UMIN000009855. Nov 20, 2012 registered. |
| first_indexed | 2024-04-10T12:52:30Z |
| format | Article |
| id | doaj.art-2eae8b50c1884c4e9fe02f8df11abfb5 |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T12:52:30Z |
| publishDate | 2018-10-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-2eae8b50c1884c4e9fe02f8df11abfb52023-02-15T16:13:39ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312018-10-0114419419810.5152/ejbh.2018.417413049054QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast CancerHiromi Okuyama0Seigo Nakamura1Sadako Akashi-Tanaka2Terumasa Sawada3Takashi Kuwayama4Satoko Handa5Yasuhisa Kato6 Division of Drug Information Analytics, Department of Drug Information, Showa University School of Pharmacy, Tokyo, Japan Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan Division of Drug Information Analytics, Department of Drug Information, Showa University School of Pharmacy, Tokyo, Japan Division of Drug Information Analytics, Department of Drug Information, Showa University School of Pharmacy, Tokyo, Japan Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of Cancer Therapy-Breast (FACT-B), as a measure of health-related quality of life (HRQoL).Materials and Methods: Stage I–III HER2-negative breast cancer patients from the previous study were included. They received either four cycles of nab-PTX (100 mg/m2 days 1/8/15) every 4 weeks, or DTX (75 mg/m2 day 1) every 3 weeks, both followed by four cycles of 5-fluorouracil/ epirubicin/cyclophosphamide (FEC). Patients completed a health-related quality-of-life questionnaire at baseline, after one and four cycles of taxanes, before administration of FEC, and after administration of one and four cycles of FEC.Results: Thirty-six eligible patients were enrolled. The baseline characteristics of the two groups were well balanced. FACT-B scores at baseline and after four cycles of taxanes were 115/108 (DTX/nab-PTX) and 99/92, respectively. There were no significant differences between DTX and nab-PTX for FACT-B, FACT-B-Trial Outcome Index (FACT-B-TOI) and FACT-General. FACT-B and FACT-B TOI scores tended to decrease after one cycle and after four cycles of chemotherapy which did not recover to the baseline scores through the end of chemotherapy in each group.Conclusion: There were no significant safety differences between nab-PTX and DTX. HRQoL tended to decrease during taxane-based anticancer treatment, with no significant differences between the treatments. We suggest that the HRQoL questionnaire has limited ability to evaluate different chemotherapy schedules. Trial registration UMIN000009855. Nov 20, 2012 registered. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023 breast cancer therapyside effectquality of lifepatient support system |
| spellingShingle | Hiromi Okuyama Seigo Nakamura Sadako Akashi-Tanaka Terumasa Sawada Takashi Kuwayama Satoko Handa Yasuhisa Kato QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer European Journal of Breast Health breast cancer therapy side effect quality of life patient support system |
| title | QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer |
| title_full | QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer |
| title_fullStr | QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer |
| title_full_unstemmed | QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer |
| title_short | QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer |
| title_sort | qol evaluation of nab paclitaxel and docetaxel for early breast cancer |
| topic | breast cancer therapy side effect quality of life patient support system |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023
|
| work_keys_str_mv | AT hiromiokuyama qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT seigonakamura qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT sadakoakashitanaka qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT terumasasawada qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT takashikuwayama qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT satokohanda qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer AT yasuhisakato qolevaluationofnabpaclitaxelanddocetaxelforearlybreastcancer |